Physician profile
Sonalee Ravi
NPI 1710320775
$1,807.33
in general payments reported to CMS, 2019-2025
19 companies · $821 in 2025
The $821 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2023: $55.22 · 2024: $825 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,701.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $484.48 | 2024-2025 | Dexcom G6 Transmitter |
| Ascendis Pharma Endocrinology INC | $230.38 | 2023-2025 | Skytrofa |
| Arbor Pharmaceuticals, INC. | $106.18 | 2019 | |
| Azurity Pharmaceuticals, INC. | $105.30 | 2024 | Triptodur |
| Novo Nordisk INC | $103.82 | 2024-2025 | Sogroya |
| Xeris Pharmaceuticals, INC. | $102.13 | 2024 | Gvoke Hypopen |
| Endo USA, INC. | $96.29 | 2024-2025 | Supprelin |
| Abbott Laboratories | $82.83 | 2024-2025 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $78.18 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascensia Diabetes Care US INC. | $65.28 | 2024-2025 | |
| Insulet Corporation | $64.18 | 2024 | Omnipod |
| Tolmar, INC. | $54.72 | 2024-2025 | Fensolvi |
| Abbvie INC. | $50.46 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $46.77 | 2024 | |
| Sequel Med Tech, LLC | $37.72 | 2025 | Twiist |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $33.01 | 2023 | Trulicity, Mounjaro |
| Pfizer INC. | $25.31 | 2025 | |
| Beta Bionics, INC. | $23.65 | 2024 | Ilet Bionic Pancreas |
| Amphastar Pharmaceuticals, INC. | $16.64 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonalee Ravi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.